• leader board size

News

Vireo Growth Acquires PharmaCann Colorado Assets

DENVER – Vireo Growth Inc. reached an agreement with PharmaCann Inc. to buy its 17 operational dispensaries and related assets in Colorado for roughly $49 million in company shares, a move that bolsters Vireo's retail presence in one of the nation's longtime recreational Cannabis states. The all-stock transaction marks another step in Vireo's push to ...

December 19th, 2025|M&As, MSOs, Retail|

🚨🚨 BREAKING: TRUMP RESCHEDULES CANNABIS 🚨🚨

WASHINGTON, D.C. –After months of speculation, President Trump Issues Executive Order Directing Federal Rescheduling of Cannabis to Schedule III President Donald Trump has signed an executive order directing federal agencies to complete the rescheduling of Cannabis from Schedule I to Schedule III under the Controlled Substances Act. This is the most significant federal Cannabis policy ...

December 18th, 2025|Business, Insights|

Michigan Senate Tightens Controls on Intoxicating Hemp Derivatives

LANSING – In a bipartisan push to close regulatory gaps, the Michigan Senate approved a package of bills that would classify most high-potency hemp-derived THC items as Cannabis, folding them into the state's established Cannabis oversight system. The measures, which cleared on 27-8 votes, now head to the Republican-led House for review when lawmakers reconvene ...

December 18th, 2025|Local Politics, Markets|

Trulieve Secures $140M in Senior Notes

TALLAHASSEE – Trulieve Cannabis Corp. wrapped up a $140 million private placement of 10.5% senior secured notes, tapping into robust investor appetite to fuel its operational push. The deal, upsized from initial plans, comes just weeks after the company cleared out its entire $368 million tranche of 8% notes due in 2026, signaling a deliberate ...

December 18th, 2025|Capital, MSOs|

Czech Republic Approves Psilocybin Therapy Guidelines for 2026

PRAGUE – The Czech Republic has taken a measured step toward integrating psychedelic-assisted therapy into its healthcare system, approving detailed rules that will permit the controlled use of psilocybin for select patients beginning in January 2026. This development, rooted in a recent amendment to the nation's criminal code, positions the country as Europe's early adopter ...

December 17th, 2025|Psychedelics|

MSOS ETF Rally Hints at Bigger Gains Ahead, Zuanic Report Finds

LOS ANGELES – A recent report from equity research firm Zuanic & Associates outlines substantial financial gains for U.S. MSOs if federal regulators shift Cannabis to Schedule III status, with savings potentially exceeding hundreds of millions in back taxes alone. Authored by Wall Street analyst Pablo Zuanic, the document, titled "US MSOs: The S3 Math ...

December 17th, 2025|Insights|

Organigram Reports Q4 2025 Financial and Full Fiscal Year Results

TORONTO – Organigram Global Inc. released its record Q4 and fiscal 2025 results, showing substantial gains in revenue and profitability metrics despite a quarterly net loss tied to one-time charges. For the fourth quarter, gross revenue reached $123.3 million, up 76% from the prior year, while net revenue climbed 79% to $80.1 million. The adjusted ...

December 17th, 2025|Report|

The Supreme Court Declines to Resolve Federal Cannabis Prohibition—And the Silence Speaks Volumes

WASHINGTON, D.C. – In its December Orders List, the U.S. Supreme Court declined to hear a case that many hoped would finally force a reckoning between federal Cannabis prohibition and state-legal markets. By declining review, the Court effectively allows existing federal law to remain in place without comment, despite the widespread legalization of Cannabis at ...

December 16th, 2025|Business, Insights|

Canopy Growth Acquires MTL Cannabis in Bid to Ramp Up Medical Sales

SMITHS FALLS – Canopy Growth Corp., a major player in the Canadian Cannabis sector, has signed a definitive agreement to purchase MTL Cannabis Corp. in a cash-and-stock transaction worth about $125 million on a fully diluted basis. The deal, which carries an enterprise value of roughly $179 million, aims to position the combined operation as ...

December 16th, 2025|M&As|

Trump Sets Plans for Cannabis Reclassification Executive Order

WASHINGTON – President Donald Trump is set to direct federal agencies to reclassify Cannabis from its current Schedule I status to Schedule III under the Controlled Substances Act, a step that would align federal oversight with drugs like certain pain relievers and anabolic steroids. The anticipated executive order would mark a significant adjustment in national ...

December 12th, 2025|US Politics|

Mid-Cap Cannabis Operators Face Liquidity Pressures Despite Solid Leverage, Viridian Report Finds

LOS ANGELES – Public Cannabis companies with $25-100 million market values are navigating a patchwork of financial strengths and vulnerabilities, according to the latest Weekly Credit Report from Viridian Capital Advisors. It tracks eight U.S.-based cultivation and retail companies, revealing a sector where half the group can cover short-term obligations without fresh capital, but several ...

December 11th, 2025|Insights|

Ascend Wellness Partners with Cannabis Advocate for New Dispensary in New Jersey

NEW YORK – Ascend Wellness Holdings Inc. disclosed a partnership with Mister Jones LLC and industry advocate Lerone Jones to launch a retail dispensary in Little Falls, NJ. The arrangement, one of the initial deals enabled by state legislation expanding investment in minority- and women-owned Cannabis ventures, positions the companies to open doors on December ...

December 11th, 2025|Business|

Grown Rogue Claims Ground in Minnesota

MINNEAPOLIS – Grown Rogue International Inc., a Сannabis MSO focused on premium flower, has signed a long-term lease for a 109,000-square-foot facility in Fridley, just north of Minneapolis, positioning the company to produce for the state's adult-use market. The deal comes as Minnesota's recreational sales kicked off in September 2025, two years after voters approved ...

December 11th, 2025|Business, MSOs|

New Mexico Speeds Up Psilocybin Therapy Access

SANTA FE – State health leaders in New Mexico outlined plans this week to open a regulated psilocybin therapy program by the close of 2026, advancing the timeline a full year from the original statutory target. The move, shared during the inaugural session of the Medical Psilocybin Advisory Board, reflects strong public demand and positions ...

December 10th, 2025|Psychedelics|

Stiiizy Expands California Retail Network Buying 12 Gold Flora Outlets

LOS ANGELES – Stiiizy, the dominant player in California's Cannabis retail, has taken control of 12 former Gold Flora dispensaries in a $25 million court-approved transaction, marking a key step in the state's ongoing industry shakeout. The deal, finalized this week after an October 23 auction in Los Angeles Superior Court, adds significant square footage ...

December 10th, 2025|Retail|

Cronos Targets Europe Through Dutch Cannabis Leader Acquisition

TORONTO – Cronos Group Inc. has agreed to buy CanAdelaar B.V., the top supplier in the Netherlands' controlled adult-use Cannabis program, for $67 million upfront plus performance incentives. The move marks Cronos's first major step into Europe's most developed recreational Cannabis sector. The Toronto-based company's subsidiary signed a binding share purchase contract on December 9, ...

December 10th, 2025|Business, M&As|

Craft Cannabis Market Projects Steady Climb to $12.3B by 2031

LOS ANGELES – Small-scale producers in the Cannabis industry are gaining ground as buyers turn toward premium, handcrafted options, with the craft segment expected to double in value over the next five years. A report from Market Research Intellect forecasts the global craft Cannabis market at $5 billion for 2025, on pace to hit $12.3 ...

December 9th, 2025|Markets, Report|

FDA Signals Shift to Single Phase 3 Trials for Drug Approvals, Opening Door for Faster Psychedelic Therapies

LOS ANGELES – The Food and Drug Administration is preparing to overhaul its evidence requirements for new drug approvals, making a single well-designed Phase 3 trial the standard rather than the exception. This adjustment, outlined by agency Commissioner Marty Makary, could streamline paths to market for therapies in mental health, including experimental psychedelic treatments for ...

December 9th, 2025|Psychedelics|

OPINION: MJBizCon25 Review: The Race To Be Second

LAS VEGAS- Gosh… the MJBizCon I attended was awesome — genuinely one of the best and most productive ones I’ve ever been to — which is why I was so surprised to see how much negative commentary appeared afterward. Because the MJBizCon I experienced was vibrant, busy, and full of serious people doing serious business ...

December 8th, 2025|Business, Insights|

CRS Reveals Hemp Ban Enforcement Hurdles

WASHINGTON – The Congressional Research Service (CRS) has highlighted gaps in the federal government's plans to enforce the upcoming ban on intoxicating hemp products, raising questions about the practical reach of the law amid the sector's expansion. The report examines the redefinition of hemp tucked into the November 2025 spending bill signed by President Donald ...

December 8th, 2025|Report, US Politics|

Federal Hemp Overhaul Threatens Cannabis Seed Trade, Sparking Breeder Backlash

LOS ANGELES – A tucked-away clause in last month's federal spending package has upended the rules for Cannabis seeds, thrusting the U.S. genetics sector into uncertainty and prompting warnings from cultivators that prized strains could vanish from legal channels. The provision, embedded in H.R. 5371 and signed by Trump, redraws the line between hemp and ...

December 8th, 2025|Cultivation|

CMI Projects Double-Digit Expansion for Cannabis Testing Market

LOS ANGELES – A recent analysis from Custom Market Insights (CMI) forecasts the global Cannabis testing market to climb from $2.13 billion in 2025 to $11.15 billion by 2034, powered by a CAGR of 18%. The projection underscores how stricter quality controls in an industry still navigating patchwork regulations could sustain steady investment in lab ...

December 8th, 2025|Insights|

Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – The past fortnight delivered a surge of momentum across the U.S. Cannabis and Psychedelics sectors, where federal signals on coverage and equity met bold state actions on access and licensing. Operators navigated stock adjustments and acquisition plays, while research breakthroughs hinted at broader therapeutic frontiers. Investors watched closely as these developments underscored ...

December 8th, 2025|Business, The Week in Review|

Psychedelics Advance in Federal Arena as Trials and Policies Align

LOS ANGELES – Federal health officials under the Trump administration have begun to signal stronger backing for psychedelic therapies, setting the stage for possible FDA approvals of MDMA and psilocybin treatments within the next 18 months, according to recent conversations with regulators, lawmakers, and industry executives. This shift comes as developers ramp up lobbying efforts ...

December 5th, 2025|Psychedelics|
Go to Top